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04.4
Introduction to Interventional Treatment for
Critical Limb Ischaemia
The decision to proceed with vascular intervention on
a patient with CLI is relatively straightforward,
because most require revascularisation to avoid major
amputation. The decision regarding the most appro-
priate intervention, however, is complex, with a num-
ber of factors requiring consideration. In addition to
the mortality and morbidity, comorbid risk factors and
life expectancy must be weighed against the initial
success and long-term durability of the chosen inter-
vention. The literature can provide only broad direc-
tion in the decision-making process because most
series report best results in a selected patient popula-
tion characterised by more favourable anatomic lesions.
Ideally, the patient should be treated with the least
risky and least morbid but most successful an-d
durable procedure. Comorbid risk factors will modify
this ideal to give priority to patient safety. High-risk,
frail patients may be best treated with less invasive
interventions, even though durability may not be opti-
mal. In some patients, revascularisation procedures
should be abandoned for primary amputation when
patient factors suggest extremely high morbidity and
mortality or the arterial anatomy predicts a poor out-
come of intervention. Conversely, the temptation to
pursue the least invasive procedure even in the
healthy individual should be resisted. In such cases,
the durability of the procedure over many years is
important in reducing lifetime morbidity and cost.
In the following discussions, the results of open sur-
gical and endovascular procedures are presented sep-
arately in relation to proximal and distal levels of
occlusive disease: aortoiliac or infra inguinal. This is
followed by a discussion of the usually preferred
option for each broad category of lesion: aortoiliac or
infrainguinal. The disease at each level not only must
be considered in terms of its own severity, but all lev-
els of disease must be combined in considering the
best approach to limb salvage and improved function.
This is particularly true of CLI, in which multilevel
occlusive disease predominates and poor runoff is
almost the norm. Although it is necessary to present
the results of open surgical and endovascular inter-
ventions separately, they ultimately must be consid-
ered together. Unfortunately, there is a tendency to
choose either surgical or percutaneous revascularisa-
tion techniques exclusively in a given patient, but a
multidisciplinary approach results in better choices, as
may combining procedures. Excellent results may be
obtained when endovascular and open surgical proce-
dures are combined (eg, combined iliac dilatation with
distal surgical revascularisation).
Given the multilevel nature of the disease in
patients with CLI and the lack of sufficient data in the
literature dealing with each of the multiple combina-
tions of disease, it is not possible to make recommen-
dations that cover all eventuality. In principle, how-
ever, the most appropriate treatment should be
applied to each individual occlusive lesion, and com-
binations of treatment modalities should be consid-
ered as well as procedures that span more than one
level of disease. These and the other considerations
previously mentioned should be kept in mind in the
discussions that follow. In the following sections,
results from a variety of studies are presented. It is
imperative that the individual caring for the patient
with CLI review the results obtained at their own
institution (see also Recommendation 77, p 5150, and
D 4.15, Vascular Registry Data, p 5220).
Recommendation 87: Choosing between techniques
with comparable short- and long-tenn benefit
When two techniques of revascularisation
(endovascular and open surgery) give equivalent
short-term and long-term benefit, the technique
with the least morbidity and mortality must be
used first. Cost also should be considered.
Recommendation repeatedfrom preoioussection, sec
v5150
Recommendation 77:
It is recommended that all units dealing toith critical
limb iscltacntia mail/tail/ accurate, audited records
for patients treated and their progress. The minimum
follOW-III' anabjsis should be ill terms of l-ycar re-
interventions, re-admissions, amputation rates,
mortality, and, ideally, other outcome measures.
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D 4.5
Aortoiliac Disease-Surgical Treatment
04.5.1
Introduction
The surgical treatment of aortoiliac disease offers bet-
ter results, in terms of degree and duration of benefit,
than surgical treatment of more distal lesions.
However, it is also generally associated with greater
morbidity than infra inguinal reconstruction, although
the mortality risk is similar, primarily because of the
higher incidence of diabetes (and thus systemic ather-
osclerosis) in the latter group'! Whether one is dealing
with primarily unilateral (iliac artery) occlusive dis-
ease or bilateral disease (aortoiliac or bilateral iliac)
has major bearing on the choice of treatment and par-
ticularly the choice between bypass or endovascular
revascularisation. To permit the separation of bilateral
(usually more diffuse) disease from more localised
unilateral disease, operations to treat each of these
conditions have been addressed separately.
o 4.5.2
Bilateral Disease
The aoriobijemoral bypass
The aortobifernoral bypass (ABF) is considered the ref-
erence standard of treatment for aortoiliac occlusive
disease, because it produces the best and most reliable
overall results (see Table 42). However, because most
patients with claudication and limited lesions are now
treated by endovascular procedures, ABF is in general
reserved for those with extensive lesions and CLI
rather than those with claudication. The stability of
modem graft materials and the durability of benefit in
those patients who have undergone ABF grafting is
such that other revascularisation procedures for aor-
toiliac disease must be compared with it. A number of
alternatives to the standard approach through a verti-
cal incision have been suggested, including a trans-
verse incision,2 retroperitoneal,3 and more recently,
minimally invasive and laparoscopic approach.'
Overall patency rates are not different when end-to-
end versus end-to-side upper anastomoses are proper-
ly compared.w? Therefore, other considerations
should dictate the configuration of the aortic anasto-
mosis. These include preservation of blood flow into
the inferior mesenteric and internal iliac arteries,
preservation of the hypogastric arteries, which may
reduce the incidence of impotence, aneurysmal
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changes, the aorta as a source of emboli, and juxta-
renal aortic occlusion.
Aortoiliac endarterectomy
The durability of aortobifemoral bypass grafting led
to a decrease in the performance of this more techni-
cally challenging operation. Most centres reserve
endarterectomy for young patients with very
localised disease, but, for the most part, aortoiliac
endarterectomy now competes (unfavourably) with
PTA and stenting.
The possible requirement for future aortic surgery
should temper enthusiasm for this procedure except
in the ideal patient," Risks of infection are low, and
internal iliac flow is preserved. It avoids the risk of
graft infection, and this promotes its use in patients
with an ongoing increased risk of sepsis caused by
infectious diseases elsewhere (eg, recurrent urinary
sepsis). In one study, a 10-year patency rate of 90.4%
was reported, but in over half of these patients the
indication for surgery was claudication, and other
authors have not attained similar good results."
Selected results of primary patency rates for aortoiliac-
femoral endarterectomies are presented in Table 44,
with 5-year patency rates ranging from 60% to 94%.
Most studies have a low incidence of operations for
CLI, and where compared, patency rates are clearly
better in patients treated for claudication. More
localised endarterectomies also offer more favourable
results than those of the entire aortofemoral segment.
04.5.3
Tabulated Results for Aortoiliac Reconstruction
Treatment comparisons of surgical and endovascular
modalities are not always stratified into unilateral
(iliac artery) and bilateral (aortoiliac and bilateral iliac)
disease in the reported literature. The excellent paten-
cy rates for aortobifemoral bypass grafts reflect good
functional results (see Table 42). It should be noted
that, in many of the studies cited, most subjects
were patients with intermittent claudication.
Approximately 95% of patients are initially rendered
asymptomatic or improved, and after 5 years, approx-
imately 80% to 90% remain in this category," A study
from the United Kingdom indicates that, of patients
fully employed before aortobifemoral bypass, 85%
return to full employment an average of 4 months
after surgery." It should be noted that in this table
some older series, although reporting good patencies,
not unexpectedly have higher mortality rates.
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Table42: Primary patency resulls for aortobifernoral bypass ranked by percentage CLl patients and total sample size (select-
ed reports)
Primary patency (%)
Operative
Patients % CLl mortality (%) 1 yr 3 yrs 5 yrs 10 yrs Comments
>50% patients with CLl
Prendiville 13-1 limbs 75 3 94 89 CFA anastomosis
et al, 199212
Prendiville 151 limbs 65 3 95 92 PFA anastomosis
et at, 199212
Schneider 79 59 1.3 85
et al, 19911J
Harris 177 59 4 91 incl23 unilat.
et at, 1985u procedures
Schneider 107 53 1 85
et al, 199213
Nevelsteen 912 53 5 94 83
et al, 199116
Brewster & 261 52 1.9 99 95 91 data from 1970-77
Darling, 197817
<50% patientsuiitl:eLl
Mulcare 114 46 8.8 98 95
et al, 19781s
Ameli 105 42 5.7 93
et al, 19891•
Lillooy 224 37 4.9 97 90 88 73
et at, 1993'0
Dunn 192 36 3 96 89 86
et al, 198221
Friedman 3-1 35 0 100 100 98 PTFE graft
et al, 199522
Friedman 26 31 0 100 100 93 Dacron graft
et at, 199522
Naylor 241 29 94 83 81
et at, 1989:!.J
Poulias 820 29 3.3 89 82
et at, 199224
Martinez et 376 28 5.6 95 92 88 78
al, 1980~
Mason 59 25 7 92 89
et aI, 198926
van den Akker 518 23 3.3 90
et al, 199227
Melliere III 22 1.8 91 end to side
et at, 19907
Jensen & 56 21 0 96 92 89%@4yrs
Egeblad ,199029
van der Vleit 350 19 4.9 93.4 88.4 86.4 8004
et al, 199430
Table 43: Meta-analysis of primary patency in reconstructions performed after 1975 in patients with CLI 31
5-year primary patency:
Limb-based 87.5% (SOn88)
Patient-based 80.4% (72-82)
10-year primary patency:
Limb-based 81.8% (70-85)
Palielll-based 72.1% (61-76)
Operative mortality 3.3%
Systemic morbidity 8.3%
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Table 44: Results of primary palency rales from reports of aortoiliofemoral endarterectomy (selected reports)
Operative Patency
Patients %CLI mortality (%) 1 yr 3 yrs 5 yrs
Roder et al, 198516 55 67 1.7 60
van den Dungen et al, 1991~7 93 39 0 94 83
Vitale & Inahara, 1990" 60 35 0 88 86 80
Oskam et al, 199619 94 11 0 83 68
Brewster & Darling, 197917 253 2.9 98 95 94
195 7.6 95 85 80
92 1 66
Lazaro et al, 1988;! 31 0 75
Comments
aortoiliac
aortoiliac-
femoral
iliofemoral
aortoiliac
In a meta-analysis of pooled data from 1978 to 1996,
de Vries and Huninkt' showed that after 1975 the
aggregate mortality rate had dropped from 4.6% to
3.3%, and the aggregate systemic morbidity risk
dropped from 13.1% to 8.3% (Table 43). Importantly,
this study compared limb-based patency rates for
patients with intermittent claudication and those with
CLI. For claudication, they were 91.0% and 86.8% at 5
and 10 years, respectively. This study confirms two
previous observations of the superiority of ABF over
other bypasses: (1) its remarkable durability and (2) its
patency is less affected by poor run-off, typified by
CLI patients.
Axillofellloral bypass
The axillary artery may be used as an inflow source.
Although some recent studies report excellent results
with extraanatomic bypass grafts, such as
axillofemoral bypasses, these are in general limited to
those patients with exceptional surgical risks because
of concurrent disease or to those in whom the abdom-
inal approach is contraindicated (eg, infection, multi-
ple adhesions, other intraabdominal pathological con-
ditions). The improved recent results with 5-year pri-
mary patencies of 75% to 80% are related to technical
improvements. These include the use of externally
supported prostheseswv but liberalised indications
also may playa role. In comparable cases, ABF pro-
duces better patency, but axillobifemoral bypass pro-
duces lower morbidity and mortality. This tradeoff is
more difficult to justify in good-risk patients with
intermittent claudication but it is clearly valuable in
those with CLI when there is a mandatory require-
ment for femoral inflow and the direct abdominal
approach is contraindicated by a prohibitive risk.
Adequate inflow for axillofemoral bypasses needs
to be confirmed by duplex scan before operation.
Calligaro et al54 recommended inflow arteriography
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because they found both a higher incidence of inflow
disease (25%) and the failure of noninvasive examina-
tion to detect disease in 75% of patients found to have
significant stenoses with arteriography.
Results ofaxillounifemoral and axillobifemoral
bypass grafts are presented in Table 45. Primary
patency results at 5 years (axillounifemoral, 30% to
79%; axillobifemoral, 33% to 85%) are not as good as
those for aortobifemoral bypass grafts. In series in
which the two have been compared, patency rates
have been statistically significantly better for axillo-
bifemoral than for axillounifemoral bypass, or the
mean patency rates have favored the former.
However, the cases may not be truly comparable, and
the issue of whether to always perform a bilateral
bypass even in the face of unilateral ischaemia has
never been addressed by an appropriate tria1.55,56,57,58
Critical Issue 32: Axi11obHemoral versus axi11o-
unHemoral bypass for critical limb ischaemia
There is a need to determine whether a bilateral
procedure should always be performed, even in the
case of unilateral ischaemia, when constructing an
axi11ofemoral bypass.
Thoraccfemorai bypass
The thoracic aorta may provide a suitable inflow
artery in patients with reasonable pulmonary and car-
diac function. Most authors find that the use of the
descending thoracic aorta with a retroperitoneal tun-
nel provides more acceptable operative risk and
acceptable patency rates.S9,60,61 The proximal anasto-
mosis is performed through a lower thoracotomy with
retroperitoneal tunnelling and crossover femoral
grafting to provide inflow to both legs. Five-year
patency rates of 86% have been reported.t?
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Table 45: Results of aortoiliac procedures-primary patency rates for extraanatomic bypass (selected reports)
Primary patency ('Yo)
Operative
Patients CLI ('Yo) mortality ('Yo) 1 yr 3 yrs 5 yrs
Axitlounifemoral
Aseer et al, 198555 3-1 100 5 44
Rutherford et al, 198737 27 100 13 48 19 19
Chang, 1986'1 23 100 33
Naylor et al, 199012 17 100 11 50
Hepp et al, 1988~ 90 80 5
Harrington et al, 1994U 73 71 8.3
EIMassry et al, 1993" 50 62 5 79
Axillooifemoral
Chang, 1986" 26 100 75
Aseer et al, 198555 22 100 5 50
Naylor et al, 1990'2 17 100 11 68
Rutherford et al, 198737 15 81 11 78 62 62
Passman et al, 199653 108 80 3.4 90 74 74
Hepp et al, 1988~ 22 80 5
EI Massey et al, 1993" 29 62 5 76
Harrington et al, 199413 80 50 8.3
Harris et al, 199052 76 5 93 85@4yr
Axillopopliteal
Aseer et al, 198555 55 100 8 58 45 40
Keller et al, 1992'; 41 100 20 70 43
Special considerations in proximal surgical
reoascularisations
Mallagemellt of [uxtarenal aortic occlusion (aortcfemoral
bypass) Aortic occlusion progressing to the juxtarenal
position may be treated successfully by an aorto-
bifemoral bypass graft. The aorta must be thrornbo-
endarterectomised, either through the end of the
divided infrarenal aorta ("champagne cork" opera-
tion) or through a longitudinal arteriotomy in the
infrarenal position after the renal arteries have been
protected from embolisatlon.sw The additional mor-
bidity has been reported specifically with respect to
suprarenal clamping and renal failure as long as the
clamping time of renal arteries is less than 30 minutes
and there is no embolisation of thrombotic or athero-
matous debris into the renal circulation.
Mallagement of the small "hypoplastic" aorta A subset
of patients, mainly female, have congenital markedly
small aortas. There remains controversy about the best
treatment for these patients. Aortoiliac endarterecto-
my with a patch has been advocated by some, but the
commonly preferred alternative is to use an ABF with
a wide end-to-side anastomosis. This gives acceptable
results with meticulous technique.e'
Management of coexisting infrainguinal occlusioe
disease
Many, if not most, patients with CLI have multilevel
disease. Brewster et al65 reported that 49% of patients
undergoing aortobifemoral bypass grafts would have
occlusion of the superficial femoral artery. Many
authors have written about the ability to predict the
success of an inflow procedure alone to relieve symp-
toms and salvage the limb. The need for subsequent
bypass has been estimated to be as high as 21% to 25%,
although in Brewster et al's series only 4% were done
slrnultaneouslyws One aspect of this is assessment of
the haemodynamic significance of iliac stenoses. It is
accepted that inflow must be adequate before the per-
formance of an outflow procedure. Complete occlu-
sions are easy to assess angiographically, but stenoses
are difficult to gauge. Haemodynamically significant
stenoses may be missed on AP projections because
iliac plaques build up posteriorly. Even biplanar views
may misjudge them. Conventional thinking is that
proximal revascularisation will suffice in most cases
(approximately 75%-85%). Identifying characteristics
of the remainder include (1) the proximal lesion is of
modest haemodynamic significance; (2) there is occlu-
sive disease in the profundageniculate collateral path-
way beyond that which can be dealt with by concomi-
tant profundaplasty; (3) the popliteal artery or two of
its branches are occluded (poor runoff); and most
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importantly, (4) there is major tissue loss or infection
in the foot.
The measurement of pressure gradients across the
aortoiliac segment after the administration such as
papaverine has been deemed a suitable assessment of
aortoiliac stenosis in determining the need for an
inflow versus an outflow procedure." Occasionally a
drop in pressure will be evident only after distal
reconstruction, and therefore these pressures should
be rnonitored.w There was no difference in infragenic-
ulate graft patency at 4 years when the anatomic
degree of proximal iliac stenosis is compared.s? It must
be stressed that it is the systolic component of the arte-
rial pressure that most accurately reflects the underly-
ing haemodynamic status of the arterial segment
being examined.w" Although pressure gradient meas-
urement can be done readily during preprocedural
arteriography, it is less desirable as a separate proce-
dure. For this reason, noninvasive imaging has been
explored as a substitute. The mean sensitivity of the
clinical evaluation for aortoiliac disease has been
reported to be in the range 32% to 77%, which is not
adequate for routine screening."
Duplex scanning was found to be the most reliable
single noninvasive test for aortoiliac disease, with a
mean sensitivity of 92%.73 Although duplex scanning
usually gives a clear result, occasionally lesions are
close to the threshold between haemodynamically sig-
nificant and insignificant lesions, and it is not possible
in some patients (eg, because of obesity or intestinal
gas). MRA is gaining recognition as an appropriate
assessment of aortoiliac occlusive disease (sensitivity,
92%; specificity, 88%).74 Such borderline lesions
require intraarterial pressure measurement with
hyperaemia at the time of arteriography. Hyperaemia
can be induced either pharmacologically or mechani-
cally. Such measurements ideally should be per-
formed before reconstruction but also can be per-
formed at time of surgery on the operating table.
Contrast arteriography with pressure measurements,
both at rest and after vasodilatation, is considered to
be the reference standard, but duplex can distinguish
all but the borderline lesions with accuracy.75,76,77,78,79
There remains considerable controversy over what
constitutes the threshold value for haemodynamically
significant pressure gradients, but it is generally
accepted that peak systolic differences of 5 to 10 mm
Hg at rest and 10 to 15 mm Hg after vasodilatation are
important (see I3 4.3.3, Aortoiliac Stents, p S86).
Presuming significant proximal disease requiring
revascularisation is present, the other main considera-
tion is whether the coexisting distal disease must be
dealt with by concomitant bypass or profundaplasty,
or whether a proximal rcvascularisation alone will
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Recommendation 88: Intraarterial pressure measure-
ments for assessment of multilevel disease
In a patient with multilevel disease, if there is
doubt about the haemodynamic significance of par-
tially occlusive aortoiliac disease, it should be
determined by intraarterial pressure measurements
at rest and with induced hyperaemia before con-
structing an outflow bypass. This may be per-
formed at the time of angiography.
Repeatedfrom p 587
Critical Issue 11: Use o/pressure gradiellts to asscss
Izaemodyll{lll1ic sigllWcmlce o/stclloses
Pressure gradient criteria uiith or tuitltout vasodila-
tors for assessing lutemodunantic significance ill
iliac lesions remain to be established.
Critical Issue 33: Effect of distal disease on iliac
artery pressure gradients
There is a need for future studies to investigate the
extent to which severe distal disease may cause an
underestimation of translesion iliac artery pressure
gradients.
suffice. Most agree that major tissue loss or infection in
the foot is an overriding consideration. In the absence
of that finding, the choice regarding profundaplasty
versus distal bypass is still a matter of debate.so
The profunda is a durable outflow artery, and, in the
presence of a superficial femoral artery occlusion and
stenosis of the origin of the profunda femoris artery, a
profundaplasty should be performed at the time of
AI3E The value of concomitant profundaplasty when
the proximal profunda is narrowed is well established.
Even if profundaplasty is indicated and performed,
decisions regarding the need for concomitant bypass,
related to indication (3) previously discussed, needs to
be made, and this can be aided by segmental limb
pressure. The pressure index recommended for isolat-
ed profundaplasty is less useful in the face of a proxi-
mal revascularisation, However, attempts have been
made to predict the need for concomitant distal
bypass from haemodynamic data. Rutherford et aP
were able to develop a proportion formula relating the
preoperative thigh and ankle brachial indices. This
"predicted" (correlated with the presence or absence
of) haernodynamic failure when distal reconstruction
was not performed with 89% accuracy. 5 Others have
successfully incorporated this approach into their
practices."
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Table 46: Results of aortoiliac procedures-primary patency rates for unilateral reconstruction (selected reports)
Operative Primary patency (%)
CLI mortality )
Patients (%) (% 1 yr 3yr 5yr Comments
Unilateral aorto/iliaciliacljemoral bypass
Piotrowski et al, 1988'5 17 53 0 48 48 teompare with fern-fern results below'
Kalman et at, 198732 50 44 0 96 92
van der Vleit et al, 199430 184 39 2 95 88
Mason et al, 198926 39 31 0 89
Ricco, 199233 69 18 1 97 90 :j:eompare with fern-fern results belowt
Femorcfemoral bypass
Hepp et al, 19883-1 26 80 4 100 80
Lorenzi et al, 199435 165 67 4.2 91 81 75
Kalman et al, 198736 82 52 0 80 6773
Perler & Williams, 1996'9 26 46 1.4 87 79 79
Perler & Williams, 1996'9 44 50 1.4 81 73 59 with donor artery dilatation
Rutherford et at, 198737 60 45 0 79 67 67 without donor artery dilatation
Criado et al, 199338 110 44 4.5 83 71 60
Piotrowski et al, 198835 47 40 0 60 55 teompare with iliofem results above'
Ng et al, 199239 156 34 1.3 92
Ricco 199233 74 17 1 92 79 :j:eompare with iliofem results abovet
Farber 199(}lO 71 4 82
Chang 1986~1 53 85
D 4.5.4
Unilateral Iliac Disease
Unilateral aorto or iliac tofemoral bypass
When a single iliac artery is involved in the ischaemic
process, it may be desirable to conduct a unilateral
procedure. Several studies suggest that unilateral
aorta femoral bypass grafts can be safely performed
and may have higher patency rates than extraanatom-
ic bypass grafts.» The iliac artery also may provide a
suitable inflow artery.82-830 8-1 The risk of progression of
occlusive disease in the contralateral iliac artery and
the need for subsequent reconstruction has given rise
to cautionary note by some authors who prefer to per-
form a bilateral reconstructlon.evs
Femorojemoral bypass
Comparative studies have failed to yield comparable
success rates for extraanatomic bypass grafts when
compared with the standard ABF, probably attributa-
ble in part to progressive disease in the donor limb.87oSS
Thus, the inflow arterial system must be of an excel-
lent quality if good results are to be obtained with
crossover bypasses. Inflow may be improved with
PTA before crossover femoral grafting in those with
some donor iliac artery stenosis. Comparative studies
have shown similar patency rates when donor arteries
are dilated or stented before bypass in carefully select-
Critical Issue 34: Long-term results of crossover
bypass grafts
There is a need for randomised studies comparing
long-term results of crossover femorofemoral
bypass, iliofemoral bypasses, or endarterectomy
and direct aortofemoral bypasses.
ed patients.e? It is recommended that donor iliac artery
PTA or stenting should be reserved for the ideal
lesions.
Results of direct revascularisation and crossover
grafts are depicted in Table 46. Controversy exists
over which of the two main choices of operation is
preferred. In addition, unless the disease is truly
localised to the unilateral iliac system or the patient's
condition precludes an aortic procedure, ABF is rec-
ommended as the inflow procedure of choice.s?
Axillounifemoral bypass
The application of this bypass is limited, because of its
lower patency rate, primarily to secondary operations
for graft infections. It also is used in situations in
which there is a pressing need for unilateral inflow but
other inflow donor arteries are not patent or accessible
because of hostile anatomy or prohibitive anaesthetic
risk (see also Table 45, p SI77).
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